COVID-19核酸増幅検査（NAAT）市場：パイプラインレポート（開発段階、セグメント、地域・国、規制経路、主要企業）、2023年最新版

NAATは、SARS-CoV-2ウイルスの特定の核酸配列を標的として増幅します。NAATは抗原同定法と比較して優れた感度を示します。異なるタイプのSARS-Cov-2を検出するために、PCRでは複数の標的が使用されます。

当レポートでは、COVID-19核酸増幅検査（NAAT）市場について調査し、製品概要と開発中のパイプライン製品動向、様々な開発段階にある製品の比較分析や進行中の臨床試験に関する情報、参入企業の最近の動向などを提供しています。

目次

第1章 目次

第2章 イントロダクション

第3章 開発中の製品

• COVID-19核酸増幅検査（NAAT） - 開発段階別パイプライン製品
• COVID-19核酸増幅検査（NAAT） - 地域別パイプライン製品
• COVID-19核酸増幅検査（NAAT） - 規制経路別パイプライン製品
• COVID-19核酸増幅検査（NAAT） - 進行中の臨床試験

第4章 COVID-19核酸増幅検査（NAAT）- 企業が開発中のパイプライン製品

• COVID-19核酸増幅検査（NAAT）企業- 開発段階別のパイプライン製品
• COVID-19核酸増幅検査（NAAT）- 開発段階別のパイプライン製品

第5章 COVID-19核酸増幅検査（NAAT）企業と製品概要

• Age Labs ASの企業概要
• Chengdu One-Chip Biotechnology Co Ltdの企業概要

第6章 COVID-19核酸増幅検査（NAAT）- 最近の開発

第7章 付録

List of Tables

List of Tables

• COVID 19 Nucleic Acid Amplification Tests (NAATs) - Pipeline Products by Stage of Development
• COVID 19 Nucleic Acid Amplification Tests (NAATs) - Pipeline Products by Territory
• COVID 19 Nucleic Acid Amplification Tests (NAATs) - Pipeline Products by Regulatory Path
• COVID 19 Nucleic Acid Amplification Tests (NAATs) - Ongoing Clinical Trials
• COVID 19 Nucleic Acid Amplification Tests (NAATs) Companies - Pipeline Products by Stage of Development
• COVID 19 Nucleic Acid Amplification Tests (NAATs) - Pipeline Products by Stage of Development
• Glossary

List of Figures

List of Figures

• COVID 19 Nucleic Acid Amplification Tests (NAATs) - Pipeline Products by Stage of Development
• COVID 19 Nucleic Acid Amplification Tests (NAATs) - Pipeline Products by Territory
• COVID 19 Nucleic Acid Amplification Tests (NAATs) - Pipeline Products by Regulatory Path
• COVID 19 Nucleic Acid Amplification Tests (NAATs) - Ongoing Clinical Trials

Abstract

GlobalData's Medical Devices sector report, "COVID 19 Nucleic Acid Amplification Tests (NAATs) Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2023 Update" provides comprehensive information about the COVID 19 Nucleic Acid Amplification Tests (NAATs) pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.

NAAT involves amplification of specific nucleic acid sequences of SARS-CoV-2 virus by targeting specific nucleic acid sequences. NAAT exhibits better sensitivity in comparison to antigen identification methods. Multiple targets are used in PCR to detect the different types of SARS-Cov-2.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

• Extensive coverage of the COVID 19 Nucleic Acid Amplification Tests (NAATs) under development
• The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
• The report reviews the major players involved in the development of COVID 19 Nucleic Acid Amplification Tests (NAATs) and list all their pipeline projects
• The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
• The report provides key clinical trial data of ongoing trials specific to pipeline products
• Recent developments in the segment / industry

Reasons to Buy

The report enables you to -

• Formulate significant competitor information, analysis, and insights to improve R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
• Identify and understand important and diverse types of COVID 19 Nucleic Acid Amplification Tests (NAATs) under development
• Develop market-entry and market expansion strategies
• Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
• In-depth analysis of the product's current stage of development, territory and estimated launch date

Table of Contents

1 Table of Contents

• 1.1 List of Tables
• 1.2 List of Figures

2 Introduction

• 2.1 COVID 19 Nucleic Acid Amplification Tests (NAATs) Overview

3 Products under Development

• 3.1 COVID 19 Nucleic Acid Amplification Tests (NAATs) - Pipeline Products by Stage of Development
• 3.2 COVID 19 Nucleic Acid Amplification Tests (NAATs) - Pipeline Products by Territory
• 3.3 COVID 19 Nucleic Acid Amplification Tests (NAATs) - Pipeline Products by Regulatory Path
• 3.4 COVID 19 Nucleic Acid Amplification Tests (NAATs) - Ongoing Clinical Trials

4 COVID 19 Nucleic Acid Amplification Tests (NAATs) - Pipeline Products under Development by Companies

• 4.1 COVID 19 Nucleic Acid Amplification Tests (NAATs) Companies - Pipeline Products by Stage of Development
• 4.2 COVID 19 Nucleic Acid Amplification Tests (NAATs) - Pipeline Products by Stage of Development

5 COVID 19 Nucleic Acid Amplification Tests (NAATs) Companies and Product Overview

• 5.1 Age Labs AS Company Overview
  • 5.1.1 Age Labs AS Pipeline Products & Ongoing Clinical Trials Overview
• 5.2 Chengdu One-Chip Biotechnology Co Ltd Company Overview
  • 5.2.1 Chengdu One-Chip Biotechnology Co Ltd Pipeline Products & Ongoing Clinical Trials Overview

6 COVID 19 Nucleic Acid Amplification Tests (NAATs)- Recent Developments

• 6.1 Nov 29, 2023: BioSkryb Genomics Appoints Genomics Industry Veteran Ram Laxman as Chief Commercial Officer
• 6.2 Oct 30, 2023: Cepheid Receives 510(K) Clearance For Xpert Xpress CoV-2 Plus Test
• 6.3 Mar 17, 2023: When time matters, rapid point of care testing can support treatment decisions
• 6.4 Mar 15, 2023: Cepheid receives Health Canada Licence for Xpert Xpress CoV-2 plus

7 Appendix

• 7.1 Methodology
• 7.2 About GlobalData
• 7.3 Contact Us
• 7.4 Disclaimer